-tryptamine +tryptamine . Congo red/hematoxylin staining of satellites adhered to epithelioids and matrix and transitional forms. Small (blue arrows) and large (black arrows) epithelioids (-tryptamine). Note, asymmetric telophase phenotype (red curved arrow). Matrix-adhered satellites (upper inset), satellites adhered to epithelioids (thin arrows) and transitional satellite-to-epithelioid phenotype (low inset), arrows show non-even plasma membrane (+tryptamine).
CONTROL +TRYPTAMINE 10 µm Tryptamine treatment/withdrawal Tryptamine re-treated . Differential S100 staining of transitional variants (polyclonal Ab to S100A ␣ and ␤ subunits) and MAP-2 + syncytium (mAb M12 to MAP2A/B). Satellites (thick black arrows). Note uneven plasma membrane staining in some transitional variants (blue arrows), vesicles (red arrowheads), outgrowth from satellite (yellow arrow). MAP-2 + fused elongated epithelioids (green arrows). Growth cones (arrowheads). Fig. S17. S-100, tau and NSE (human brain gamma isoenzyme) in satellites (thin arrows) and vesicles (thick arrows). S-100 + satellite clusters adhered to epithelioid (arrows) and transitional forms (arrowheads).
Fig. S18. Tryptamine-induced GFAP+neuritic swellings (red arrowheads). GFAP(+) vesicles (closed arrows), transitional satellite (yellow arrow), epithelioid (green arrow). GFAP(-) and GFAP(+) satellites in control epithelioids (arrows)
. Note that GFAP-(blue arrowheads) and GFAP+(red arrowheads) neurites outgrow from the same epithelioid. TrpRS+neurites (thin black arrows). TrpRS+neuronal plasma membrane (black thick arrow). Note that similar strong TrpRS plasma membrane staining is detected in the tryptamine-treated SH-SY5Y-derived progenitors-satellites (Fig. 8C) . 
